Optovue, based in Fremont, California, received FDA clearance for what it calls “world’s first OCT Angiography metrics” system. The AngioAnalytics system is used to image the eye much like with traditional optical coherence tomography (OCT) systems, but provides visualization of individual vessels of the superficial and deep capillary plexus along with conventional OCT.
It produces images from captured 3D data in layers, depending on what’s of interest, virtually separating and allowing to focus on specific anatomy.
No dyes are used in the process, and so is easier and faster to perform, and because of its simplicity can be done more frequently on the same patient.
The firm also received clearance for its 3D PAR three-dimensional projection artifact removal software that is used along with OCTA to allow for measurement and understanding of different areas of the images.
“AngioAnalytics and 3D PAR are game changers because they ‘erase’ overlying inner retinal blood vessel artifacts allowing for better visualization and more accurate measurement of the outer retina and choroidal structures, essential in treating the abnormal blood vessel growth (CNV membrane) that leads to blindness for patients with wet age-related macular degeneration (AMD),” said Paul E. Tornambe, M.D., F.A.C.S., with Retinal Consultants of San Diego. “In the past, we’ve relied on two-dimensional imaging to determine the presence or absence of fluid leaking from these abnormal vessels in the retina, and whether or not additional treatment is necessary with VEGF inhibitor drugs. My personal evaluation of AngioAnalytics suggests we now have another way to monitor or determine if additional treatment is necessary by documenting how the drug affects a specific CNV membrane in a specific patient, and how long that effect lasts,” added Dr. Tornambe.
Here’s a video introducting OCTA:
Product page: AngioAnalytics…